ASX
Chimeric Therapeutics
CHM:ASX•Healthcare
Sensitive ASX Announcement
CHM CORE-NK Phase 1B clinical trial achieves 60% CR/CRi
Published: 27/04/26, 09:15am (AEST)•3 pages